» Articles » PMID: 33842003

Melatonin As a Therapy in Cardiac Ischemia-reperfusion Injury: Potential Mechanisms by Which MT2 Activation Mediates Cardioprotection

Overview
Journal J Adv Res
Date 2021 Apr 12
PMID 33842003
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Previous studies reported the beneficial effects of pretreatment with melatonin on the heart during cardiac ischemia/reperfusion (I/R) injury. However, the effects of melatonin given after cardiac ischemia, as well as its comparative temporal effects are unknown. These include pretreatment, during ischemia, and at the onset of reperfusion. Also, the association between melatonin receptors and cardiac arrhythmias, mitochondrial function and dynamics, autophagy, and mitophagy during cardiac I/R have not been investigated.

Objectives: We tested two major hypotheses in this study. Firstly, the temporal effect of melatonin administration exerts different cardioprotective efficacy during cardiac I/R. Secondly, melatonin provides cardioprotective effects via MT2 activation, leading to improvement in cardiac mitochondrial function and dynamics, reduced excessive mitophagy and autophagy, and decreased cardiac arrhythmias, resulting in improved LV function.

Methods: Male rats were subjected to cardiac I/R, and divided into 4 intervention groups: vehicle, pretreatment with melatonin, melatonin given during ischemia, and melatonin given at the onset of reperfusion. In addition, either a non-specific melatonin receptor (MT) blocker or specific MT2 blocker was given to rats.

Results: Treatment with melatonin at all time points alleviated cardiac I/R injury to a similar extent, quantified by reduction in infarct size, arrhythmia score, LV dysfunction, cardiac mitochondrial dysfunction, imbalance of mitochondrial dynamics, excessive mitophagy, and a decreased Bax/Bcl2 ratio. In H9C2 cells, melatonin increased %cell viability by reducing mitochondrial dynamic imbalance and a decrease in Bax protein expression. The cardioprotective effects of melatonin were dependent on MT2 activation.

Conclusion: Melatonin given before or after ischemia exerted equal levels of cardioprotection on the heart with I/R injury, and its beneficial effects on cardiac arrhythmias, cardiac mitochondrial function and dynamics were dependent upon the activation of MT2.

Citing Articles

Melatonin as a shield against skeletal muscle damage: A study on ischemia-reperfusion injury.

Demirdas E, Arslan G, Kartal H, Erol G, Ozdem T, Yavuz B Ulus Travma Acil Cerrahi Derg. 2025; 31(2):103-111.

PMID: 39963912 PMC: 11843425. DOI: 10.14744/tjtes.2025.44890.


The UCP2/PINK1/LC3b-mediated mitophagy is involved in the protection of NRG1 against myocardial ischemia/reperfusion injury.

Li X, Li X, Tian T, Yang W, Lyv S, Cheng Y Redox Biol. 2025; 80:103511.

PMID: 39874927 PMC: 11808529. DOI: 10.1016/j.redox.2025.103511.


Melatonin inhibits ferroptosis through the ATF3/GPX4 signaling pathway to relieve myocardial ischemia-reperfusion injury in rats.

He M, Yang Y, He X, Lei R, Liu H, Yang M In Vitro Cell Dev Biol Anim. 2025; 61(2):135-148.

PMID: 39836346 DOI: 10.1007/s11626-024-00995-z.


Mitophagy in ischemic heart disease: molecular mechanisms and clinical management.

Xu S, Wang Z, Guo F, Zhang Y, Peng H, Zhang H Cell Death Dis. 2024; 15(12):934.

PMID: 39737905 PMC: 11685431. DOI: 10.1038/s41419-024-07303-3.


Melatonin alleviates aging-related heart failure through melatonin receptor 1A/B knockout in mice.

Feng Z, Liu Y, Yang Y, Bai J, Lin Q, Xia Y Heliyon. 2024; 10(18):e38098.

PMID: 39347399 PMC: 11437847. DOI: 10.1016/j.heliyon.2024.e38098.


References
1.
Liu J, Clough S, Hutchinson A, Adamah-Biassi E, Popovska-Gorevski M, Dubocovich M . MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2015; 56:361-83. PMC: 5091650. DOI: 10.1146/annurev-pharmtox-010814-124742. View

2.
Yu L, Li B, Zhang M, Jin Z, Duan W, Zhao G . Melatonin reduces PERK-eIF2α-ATF4-mediated endoplasmic reticulum stress during myocardial ischemia-reperfusion injury: role of RISK and SAFE pathways interaction. Apoptosis. 2016; 21(7):809-24. DOI: 10.1007/s10495-016-1246-1. View

3.
Thummasorn S, Shinlapawittayatorn K, Chattipakorn S, Chattipakorn N . High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction. Cardiovasc Ther. 2017; 35(5). DOI: 10.1111/1755-5922.12289. View

4.
Sanada S, Komuro I, Kitakaze M . Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol. 2011; 301(5):H1723-41. DOI: 10.1152/ajpheart.00553.2011. View

5.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter R . Melatonin and cardiovascular disease: myth or reality?. Rev Esp Cardiol (Engl Ed). 2012; 65(3):215-8. DOI: 10.1016/j.recesp.2011.10.009. View